Podcast appearances and mentions of Richard Bernstein

Episode 2801 - Vinnie Tortorich speaks with engineer Dave Feldman about cracking the code of cholesterol through his new documentary, The Cholesterol Code. https://vinnietortorich.com/2026/05/cracking-the-code-dave-feldman-episode-2801 PLEASE SUPPORT OUR SPONSORS Pure Vitamin Club Pure Coffee Club NSNG® Foods VILLA CAPPELLI EAT HAPPY KITCHEN YOU CAN WATCH THIS EPISODE ON YOUTUBE - @FitnessConfidential Podcast Vinnie's workout videos are available to purchase! Choose from a 2-day, 4-day, or 6-day workout–or buy all three at a discount! TO PURCHASE VINNIE'S WORKOUT VIDEOS, CLICK THIS LINK: https://vinnietortorich.com/workout Cracking the Code Dave is the creator of The Cholesterol Code documentary, which was recently released in April 2026. (3:00) Dave is an engineer and citizen scientist who has studied cholesterol for years. (5:30) It is a great documentary that addresses high cholesterol in an easy-to-follow manner. It also addresses the benefits of the ketogenic diet and how it may affect people differently. Nick Norwitz is well known for his N=1 experiment in lowering his cholesterol through a dietary regimen. (17:00) Dave explains Nick's experiment and the significance of the results. The experiment is not advocating eating junk food. It was a comparison and a data collection method. They discuss Dave's passion for doing a deep dive into cholesterol to create the documentary. (31:00) It took a while for Dave to convince others that it was a study worth doing. Lundquist and Dr. Matthew Budoff spearheaded the study. The study had 100% completion rate with 100 participants. Dr. Richard Bernstein was a T1 diabetic who decided to monitor his own blood sugar regularly and developed a system to do so. (58:00) But he was dismissed because no doctors believed people would bother to measure their own blood several times a day. But now both the study data and the documentary The Cholesterol Code are available, and people can become better educated. You can rent or purchase The Cholesterol Code here: https://amzn.to/4w7udAF Dave can be found on X as @realDaveFeldman, and at his website https://cholesterolcode.com/ The NSNG® VIP GROUP IS NOW CLOSED AGAIN AS OF SUNDAY, MARCH 15TH Anna's next cookbook, Eat Happy Cocktail Hour, is filled with cocktails, mocktails, and appetizers and is available for pre-order right now. If you pre-order, you'll get bonus goodies! You can preorder from a wide variety of booksellers at https://eathappycocktailhour.com/ Save your receipt from wherever you preorder, you'll need it for your bonuses! Physical Release Date is October 2026 A New Sponsor Jaspr Air Scrubbers has a discount code, VINNIE, that gets you $200 off for a limited time. Jaspr offers a lifetime warranty. Go to Jaspr.co for more information or to purchase. (1:05:00) You can book a consultation with Vinnie to get guidance on your goals. https://vinnietortorich.com/phone-consultation-2/ More News Serena has added some of her clothing suggestions and beauty product suggestions to Vinnie's Amazon Recommended Products link. Self Care, Beauty, and Grooming Products that Actually Work! https://www.amazon.com/shop/vinnietortorich/list/3GPVU29UHHPMY?ref_=aipsflist Don't forget to check out Serena Scott Thomas on Days of Our Lives on the Peacock channel. "Dirty Keto" is available on Amazon! You can purchase or rent it here.https://amzn.to/4d9agj1 Please make sure to watch, rate, and review it! Eat Happy Italian, Anna's second cookbook, is available! You can go to https://eathappyitalian.com You can order it from Vinnie's Book Club. https://amzn.to/3ucIXm Anna's recipes are in her cookbooks, on her website, and on Substack —they will spice up your day! https://annavocino.substack.com/ PURCHASE DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views it receives, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: https://vinnietortorich.com/documentaries

Award-winning macroeconomic strategist Richard Bernstein looks for situations where profits are improving, liquidity is increasing & investors “hate it” to identify winning market sectors. Dividend-paying international stocks top the list.

Gary Taubes on Rethinking Diabetes: Diet, Insulin, and the History Behind Low-Carb Treatment: Journalist Gary Taubes is author of “Rethinking Diabetes: What Science Reveals About Diet, Insulin, and Successful Treatments.” The book traces diabetes treatment history and argues that carbohydrate restriction was standard care from 1797 through the early 20th century until insulin therapy shifted practice toward drug-centered management and higher-carbohydrate diets. Taubes explains how insulin's discovery changed dietary priorities, how later technology (radioimmunoassay) revealed that most diabetes is type 2 with insulin resistance and high insulin rather than deficiency, and why giving more insulin can worsen weight gain. They discuss major trials (including ACCORD, ADVANCE, and Look AHEAD) that failed to show benefits from intensive drug-based glucose control, the influence of low-fat guidelines, Richard Bernstein's role in blood-glucose self-monitoring and low-carb control, controversies about obesity models, ketosis vs ketoacidosis, GLP-1 drugs, and LDL increases on ketogenic diets.

This episode explores one of the most important debates in markets today: whether investors are underestimating the risk of higher inflation and overconcentrating in a narrow group of growth stocks.Richard Bernstein of Janus Henderson Investors joins Excess Returns to explain why today's environment may look more like the inflationary 1960s than the 1970s, what that means for portfolios, and why many investors may be disappointed with passive index returns over the next decade.Richard walks through the implications of rising import prices, global conflict, and deglobalization, and how these forces could drive a structural shift toward higher inflation and shorter-duration investing. He also explains why market concentration, AI enthusiasm, and capital flows may be setting up a broadening opportunity across overlooked areas of the market.Follow Rich on Twitter:https://twitter.com/RBAdvisorsCompany Website:https://www.rbadvisors.comWhy investors in S&P 500 index funds may face disappointing long-term returnsThe shift from exporting disinflation to importing inflation through global tradeHow war and geopolitical conflict are influencing inflation expectations and marketsWhy today's environment resembles the 1960s “guns and butter” period more than the 1970sThe case for structurally higher inflation and a potential shift in Fed targetsWhy shorter-duration assets, dividends, and cash flow matter more in inflationary regimesThe risks of overconcentration in AI and mega-cap growth stocksHow capital flows and valuation distortions create opportunities outside the Mag 7The case for international equities and why investors are significantly underweightWhere Bernstein sees the most compelling long-term opportunities across sectors and regions00:00 Intro and why index investors could be disappointed00:01:13 War, inflation, and the impact of rising gasoline prices00:02:40 Importing inflation and the role of global trade dynamics00:03:33 1970s oil shock vs 1960s guns and butter comparison00:05:00 Why today's inflation environment may be less severe than the 1970s00:06:30 Defense spending, tax cuts, and inflation expectations00:08:54 Why Bernstein is taking the “over” on inflation and deficits00:10:00 The case for a higher long-term inflation target00:11:00 Why the Fed may resist changing its 2% inflation target00:12:00 Deglobalization and the rise of global conflict00:14:00 Global inflation dynamics and divergence across countries00:15:21 Why cash and short-duration assets may outperform00:17:00 Asset-liability mismatches and the endowment model stress00:18:23 Market concentration and parallels to the dot-com bubble00:20:00 AI as an economic story vs an investment story00:21:00 Capital flows, valuation excess, and future return expectations00:22:39 Why market broadening opportunities may emerge00:24:19 Passive flows, ETFs, and market distortions00:25:40 Where Bernstein sees sector opportunities today00:27:34 The case for dividends in an inflationary environment00:31:00 Why near-term cash flow matters more than long-term growth00:33:07 Corporate behavior, capital allocation, and rising hurdle rates00:36:02 Profit cycle strength and why the market should broaden00:41:36 Evaluating IPOs and speculative investments00:47:09 The risk of a lost decade for index investors00:50:21 Gold, commodities, and portfolio diversification00:53:48 Most attractive overlooked opportunities today00:58:06 Biggest long-term risks and what keeps Bernstein up at night

It's one of the market's best-kept secrets. An index of U.S. small- & mid-cap industrial stocks has outperformed the S&P 500 for over a decade. Award-winning strategist Richard Bernstein explains why the winning streak should continue.

Justice Richard Bernstein was born blind, but that didn't stop him from becoming a marathon runner, disability rights advocate, and Justice of the Michigan Supreme Court. In this week's video, Ralph shares stories from a local event where Bernstein spoke about perseverance, suffering, and faith—raising the big question: Why do bad things happen to good people? Ralph reflects on Bernstein's life, his campaign slogan “Life is unfair, but judges shouldn't be,” and the perfectly just Judge we have in Jesus.

Richard Haass, former President of the Council on Foreign Relations, explains how the geopolitical landscape is shifting and what it means for markets and global stability. Max Kettner, Chief Multi-Asset Strategist at HSBC, breaks down the market impact and how investors should be positioned amid volatility. Paul Sankey of Sankey Research dives into the oil market gyrations. Former CEA member Jared Bernstein discusses where the economy stands and what comes next for growth, policy and the labor market. Richard Bernstein of Janus Henderson outlines what could drive markets in the week ahead as investors prepare for key jobs data. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What do you think of continuous blood pressure monitors?Should certain supplements be taken at different times of day or apart from each other?My pediatrician couldn't provide a list of calcium-rich foods for my kids with dairy intoleranceWhat are your thoughts on the HPV vaccine?Remembering a long-ago debate with a Quackbuster

A discussion of the book "Rethinking Diabetes" by Gary TaubesCORRECTION: Transcatheter Mitral Valve Replacement (TMVR)The impact of hops on the microbiomeA listener's suggestion on avoiding microplastics

Definitions are always evolving, but how will the next decade redefine the role of the Money Laundering Reporting Officer?This week, The Laundry comes to you live from the PIMFA Financial Crime Conference 2026.Our expert host, Marit Rødevand, is joined by Aaron Guilder, MLRO at Rathbones, Evgenia Giannoulopoulou, MLRO at Rothschild & Co, and Richard Bernstein, Compliance Director & MLRO at JM Finn, to ask: What is the future for MLROs? The panel discuss: The ever-evolving challenges facing today's MLROs, how the scope of the role is shifting in a digital-first landscape, and the timeless (and new) skills required to perform the role effectively.Producer: Matthew Dunne-MilesEditor: Dominic DelargyVideographer: Loïs DunfordGet your free ticket for the The Laundry Live Oslo here! ____________________________________The Laundry podcast explores the complex world of financial crime, anti-money laundering (AML), compliance, sanctions, and global financial regulation.Hosted by Marit Rødevand, Fredrik Riiser, and Robin Lycka, each episode features in-depth conversations with leading experts from banking, fintech, regulatory bodies, and investigative journalism.Tune in as we dissect headline news, unpack regulatory trends, and examine the real-world consequences of non-compliance — all through a uniquely compliance-focused lens.The Laundry is proudly produced by Strise.Get in touch at: laundry@strise.aiSubscribe to our newsletter, Fresh Laundry, here. Hosted on Acast. See acast.com/privacy for more information.

This hour: Full coverage of the war in Iran by Carl Quintanilla, Sara Eisen, and David Faber - and the impact on global markets with a great line-up of experts. Hear from CNBC's own Michael Santoli and Rick Santelli... alongside Ian Bremmer from Eurasia Group, former Defense Secretary Mark Esper, market veteran Richard Bernstein, and Former Israel Ambassador to the U.S. Michael Oren.    Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

With early exposure to Paul Tudor Jones and then stints on the sell-side in credit research, Michael Contopoulos is now Deputy CIO of Richard Bernstein Advisors, a macro-oriented asset manager overseeing roughly $20 billion across long-only portfolios. Our discussion centers on portfolio construction in an era of extreme equity concentration and shifting global leadership.On the equity side, the firm is under-weight the most concentrated segments of U.S. equities and overweight international markets, citing valuation gaps, earnings acceleration abroad, and under-ownership by investors.Using his background in quantitative credit strategy and a Merton framework for modeling  spread risk, Michael brings a structural lens to today's corporate debt markets. Our conversation focuses on the surge in long-dated issuance tied to AI infrastructure build-outs. He argues that history rarely rewards lenders who finance capital-intensive growth booms at their peak.Drawing parallels to late-1990s telecom boom, Michael questions whether investors are being adequately compensated for duration and technology risk embedded in 40- and 50-year debt issued by hyperscalers building data centers. The core concern is twofold: that AI-driven revenue gains may not justify the scale of investment, and that infrastructure built today may not remain technologically relevant decades from now.I hope you enjoy this episode of the Alpha Exchange, my conversation with Michael Contopoulos.Editing and post-production work for this episode was provided by The Podcast Consultant (⁠https://thepodcastconsultant.com⁠)

Today's guest is Richard Bernstein, Chief Investment Officer of Richard Bernstein Advisors, which he founded in 2009. He was previously the Chief Investment Strategist at Merrill Lynch. In today's episode, Richard argues that the market is defined by rampant speculation and extreme narrowness. He explains why he's bullish on both dividend-paying and international stocks and believes crypto is the first global investment bubble. To close, he warns that corporate credit is priced for perfection, inflation risks aren't gone, and diversification is the best defense in a bubble-prone market. (0:00) Starts (1:20) Richard on market narrowness & speculation (6:21) The Earnings Expectations Life Cycle (12:33) Non-US stocks are undervalued (18:38) Small cap trends and long-term investment themes (24:14) American Industrialization Renaissance (27:10) Corporate credit risk (33:42) Is the Fed independent? (36:38) Is crypto the first global investment bubble? (41:11) The importance of financial history (46:07) Richard's most memorable investment ----- Follow Meb on X, LinkedIn and YouTube For detailed show notes, click here To learn more about our funds and follow us, subscribe to our mailing list or visit us at cambriainvestments.com ----- Sponsor: Join Alpha Architect's LIVE webinar Feb 3rd to learn if a 351 Exchange may fit your clients' needs.  Before the webinar, visit Alpha Architect's 351 Education Center for use cases, tools, FAQs, upcoming launches, and more. ----- Follow The Idea Farm: X | LinkedIn | Instagram | TikTok Interested in sponsoring the show? Email us at Feedback@TheMebFaberShow.com ----- Past guests include Ed Thorp, Richard Thaler, Jeremy Grantham, Joel Greenblatt, Campbell Harvey, Ivy Zelman, Kathryn Kaminski, Jason Calacanis, Whitney Baker, Aswath Damodaran, Howard Marks, Tom Barton, and many more.  ----- Meb's invested in some awesome startups that have passed along discounts to our listeners. Check them out here!  -----Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Learn more about your ad choices. Visit megaphone.fm/adchoices

Richard Bernstein of Richard Bernstein Advisors and Alan McKnight of Regions Wealth Management debates whether speculation has gone too far and why dividends, quality, and U.S.-focused positioning may be back in favor. The conversation then turns to Washington as policy developments and presidential missives whipsaw investors with Brian Gardner of Stifel. Technology investing in 2026 with Dom Rizzo of T. Rowe Price. Bear case on Nike with Needham analyst Tom Nikic. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Will the stock market finally broaden?  Are valuations stretched?  Will momentum stall for AI-related stocks?  Richard Bernstein provides his perspective on these questions and others, laying out risks and opportunities for investors for 2026.----------------------------------------------------------------------------------------------Subscribe Here to the ROI Podcast & other First Trust Market News Website: First Trust PortfoliosConnect with us on LinkedIn: First Trust LinkedInFollow us on X: First Trust on XSubscribe to the First Trust YouTube ChannelSubscribe to the ROI Podcast YouTube Channel

As 2025 draws to a close, we cap off the year with Rich and Jason exchanging expectations for the market and macro environment in 2026 - including thoughts on the role of the Fed. Plus, a look at positioning preferences heading into the new year. Featured are Jason Draho, Head of Asset Allocation Americas with the UBS Chief Investment Office, and Richard Bernstein, Founder, Chief Executive Officer and Chief Investment Officer of Richard Bernstein Advisors (RBA). Host: Daniel Cassidy

In this episode, we are joined by Richard Bernstein, CIO and CEO of Richard Bernstein Advisors. We discuss why this is one of the most speculative market environments he has seen in his 40-year career, why he still believes it may also be one of the best eras for patient long-term investors, and how to think about the real opportunities hiding beneath the market's current narrow leadership. Richard breaks down his profit cycle framework, shares why investors are confusing economic stories for investment stories, and explains why non-US quality stocks and dividend strategies may be primed for a comeback.Topics covered• Speculation across asset classes and why it matters• Why fundamentals still offer big opportunities• The profit cycle vs the economic cycle• Divergence between the market leaders and the broader market• Inflation, pricing power, and corporate margins• Parallels between the AI boom and the dot-com bubble• Misallocation of capital and risks to the market• The case for non-US quality stocks• Where value investing could shine again• Dividend compounding and long-term wealth building• How RBA approaches macro-driven ETF investing• What investors are getting wrong about diversification• Deglobalization, reindustrialization, and long-term themesTimestamps00:00 Intro and speculative environment01:46 Best opportunities for patient investors03:52 Profit cycle framework explained06:00 Where we are in the profit cycle07:32 What investors are missing on inflation09:12 Lessons from the dot-com era and AI comparisons13:46 What could trigger the speculative unwind17:18 Valuations, CAPE, and return expectations20:23 AI's impact on margins and productivity22:39 Can value outperform again25:41 International opportunities and quality stocks34:31 Market breadth and narrow leadership36:00 The Fed, inflation targeting, and policy risks40:11 RBA's investment process and ETF selection47:13 Diversification vs speculation behavior49:26 Misallocation of capital and market risks52:00 Deglobalization and manufacturing opportunities54:13 Closing question: Stock market vs horse race57:40 The business Richard would start today58:29 Where to follow Richard Bernstein

Mike Contopoulos rejoins Leslie Falconio for a discussion around year-end asset class performance expectations, the implications of a lower rate environment to fixed income, positioning views & more. Featuring Mike Contopoulos, Deputy Chief Investment Officer, & Director of Fixed Income for Richard Bernstein Advisors, as well as Leslie Falconio, Head of Taxable Fixed Income Strategy Americas with the UBS Chief Investment Office. Host: Daniel Cassidy

The S&P 500 eked out a record close in the final moments. Richard Bernstein of Richard Bernstein advisors helps break down the market action. Cowboys owner Jerry Jones on the business of sports, NFL team valuations and more as the Cowboys get ready to kick off the season against the Eagles. L3Harris CFO Ken Bedingfield on demand, the Golden Dome and defense tech. HubSpot CEO Yamini Rangan on the company's new AI agent tools.

Richard Bernstein, CEO and CIO of Richard Bernstein Advisors, calls this the most speculative investment climate he has ever seen in his lengthy career. The good news? As investors chase overpriced assets with negligible value, many neglected stocks are high-quality, dirt-cheap, and poised to soar. In other words, as Bernstein says, a lot of Maseratis are priced like Fords. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we highlight the biggest lessons from our Excess Returns interview with renowned strategist Richard Bernstein. We explore the paradox of today's markets: why they feel easy, and what hard truths may be hiding beneath the surface. From the risks of narrow market leadership to the role of structural flows and investor complacency, Richard shares practical lessons drawn from decades of market experience.We discuss:Why narrow markets may signal greater risk than investors realizeThe danger of mistaking easy markets for safe onesHow structural flows can prop up markets despite rising risksThe behavioral traps investors fall into during seemingly easy timesWhat history teaches us about mispricings and market resilienceWhether you're focused on protecting capital or positioning for the next cycle, this conversation offers valuable insights into today's market dynamics.

Two major narratives unfold — one on Wall Street, the other in Washington. We kick things off with market insight from Richard Bernstein of Richard Bernstein Advisors and Citi's Scott Chronert. Stifel's Brian Gardner breaks down the latest from D.C.. Evercore Chairman Emeritus and BlackRock Co-Founder Ralph Schlosstein weighs in on global M&A and the policy landscape. Plus, Morgan digs deep on the Army's autonomous push. Rocket Lab CEO Peter Beck on space demand and the stock's huge run. 

Richard Bernstein draws on over four decades of investment experience to offer insights on how to navigate risks and opportunities amid soaring economic uncertainty and market volatility. ----------------------------------------------------------------------------------------------Subscribe Here to the ROI Podcast & other First Trust Market News Website: First Trust PortfoliosConnect with us on LinkedIn: First Trust LinkedInFollow us on X: First Trust on XSubscribe to the First Trust YouTube ChannelSubscribe to the ROI Podcast YouTube Channel

Rich rejoins the conversation with Jason to exchange thoughts around the evolution of US trade policy, the current market environment, the health of the US economy, and portfolio positioning recommendations. Featured are Jason Draho, Head of Asset Allocation Americas with the UBS Chief Investment Office, and Richard Bernstein, Founder, Chief Executive Officer and Chief Investment Officer of Richard Bernstein Advisors (RBA). Host: Daniel Cassidy

On episode 193 of The Compound and Friends, ⁠⁠Michael Batnick⁠⁠ and ⁠⁠Downtown Josh Brown⁠⁠ are joined by Richard Bernstein to discuss: the Big Beautiful Bill, the bond market, the Fed, the next recession, international stocks, the best uncertainty hedge, and much more! This episode is sponsored by Kraneshares. Read their recent article on the future of AI at: https://KraneShares.com/ai Sign up for The Compound Newsletter and never miss out: ⁠⁠thecompoundnews.com/subscribe⁠⁠ Instagram: ⁠⁠instagram.com/thecompoundnews⁠⁠ Twitter: ⁠⁠twitter.com/thecompoundnews⁠⁠ LinkedIn: ⁠⁠linkedin.com/company/the-compound-media/⁠⁠ TikTok: ⁠⁠tiktok.com/@thecompoundnews⁠⁠ Investing involves the risk of loss. This podcast is for informational purposes only and should not be or regarded as personalized investment advice or relied upon for investment decisions. Michael Batnick and Josh Brown are employees of Ritholtz Wealth Management and may maintain positions in the securities discussed in this video. All opinions expressed by them are solely their own opinion and do not reflect the opinion of Ritholtz Wealth Management. The Compound Media, Incorporated, an affiliate of ⁠⁠Ritholtz Wealth Management⁠⁠, receives payment from various entities for advertisements in affiliated podcasts, blogs and emails. Inclusion of such advertisements does not constitute or imply endorsement, sponsorship or recommendation thereof, or any affiliation therewith, by the Content Creator or by Ritholtz Wealth Management or any of its employees. For additional advertisement disclaimers see here ⁠⁠https://ritholtzwealth.com/advertising-disclaimers⁠⁠. Investments in securities involve the risk of loss. Any mention of a particular security and related performance data is not a recommendation to buy or sell that security. The information provided on this website (including any information that may be accessed through this website) is not directed at any investor or category of investors and is provided solely as general information. Obviously nothing on this channel should be considered as personalized financial advice or a solicitation to buy or sell any securities. See our disclosures here: ⁠⁠https://ritholtzwealth.com/podcast-youtube-disclosures/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Markets weigh mega-cap momentum against rising caution with Ryan Detrick of Carson Group and Richard Bernstein of RBA debating. Key takeaways from Nvidia and Microsoft's moves, while Jason Furman, former CEA Chair, breaks down budget bill risks and the deficit. Plus, Dan Niles weighs in on tech and the economy and why he sees fresh lows later this year and our Leslie Picker on the quiet race to succeed Jamie Dimon.

About Only in AmericaA probing biography of world-renowned Jewish singer and actor Al Jolson and the history of his performance in and the making of The Jazz Singer.About the AuthorRICHARD BERNSTEIN has been a reporter, culture critic, and commentator for more than thirty years. He was a foreign correspondent in Asia and Europe for Time and The New York Times, and was the first bureau chief in China for Time. He is the author of several books, among them China 1945; A Girl Named Faithful Plum; Ultimate Journey, a New York Times Best Book of the Year; and Out of the Blue, named one of the seven best books of the year by The Boston Globe. He lives in New York City.

Send us a textSusan Colonna is a retired Registered Nurse, having received her Bachelor of Science degree in Nursing from Texas Woman's University in 1992. She has been passionate about natural health remedies and regular exercise for her entire life.In her 40's, Susan was a sponsored athlete and a national-level competitive bikini level bodybuilder and achieved a high level of success by taking 2nd place at the North American NPC National finals in 2014. She is the mother of 4 adult kids and is a grandmother of 2.In January of 2023 Susan was diagnosed with type one diabetes, and she witnessed firsthand how the medical system completely failed her. Today, Susan is enthusiastic about sharing her story about how medical doctors refused to give her insulin, which is insane, but instead would give Ozempic to her, which led her to experience shock, pancreatitis, and eventually a near-death experience.Today she is extremely outspoken about the benefits of the carnivore diet, and she encourages others to be their own health advocates.Find Susan at-TW- @truthhhseekerFB- @Susan Parker Colonnahttps://yandex.com/Find Boundless Body at- myboundlessbody.com Book a session with us here!

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Eli Lilly will start a lcinical trial for tirzepatide for people with type 1 diabetes, more details on Dexcom's 15 day G7 sensor, Ozepmic pill form tested, type 5 diabetes identified and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week.. Eli Lilly takes the first steps toward getting tirzepatide approved for people with type 1 diabetes. Tirzepatide is sold under the brand names Mounjaro for type 2 and Zepbound for obesity. The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or are overweight. Participation in the study will last about 49 weeks. Official Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight This is a big deal because, even though many people with type 1 are able to get a prescription for tirzepatide, it's not approved for T1D and so insurers won't usually cover it.   https://clinicaltrials.gov/study/NCT06914895 XX The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there's little information on the drugs' safety and effectiveness for the condition. The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can't make enough of their own. Drugmakers feared that using the GLP-1 medications with insulin might raise the chance of dangerously low blood sugar events, or hypoglycemia, and were unwilling to take the risk of studying them in people with type 1.   For the study, which was published last month in the journal Diabetes, Obesity, and Metabolism, researchers at Johns Hopkins University reviewed the medical records of more than 200,000 people with type 1 diabetes from 2008 to 2023. They grouped the data in three-year periods, starting with October 2008 to September 2011 and ending with October 2020 to September 2023. GLP-1 medication use spiked, as well. Among adults with the highest category of obesity, about 4% used GLP-1 medications in 2008, and 33% did by 2023 – an 800% increase. But these are anecdotal reports and may not reflect instances in which people have side effects or complications like low blood sugar, which can be life-threatening. But Shin says what's really needed is information from randomized, double-blinded studies, in which participants are followed forward in time and given either a drug or a placebo. https://www.cnn.com/2025/04/09/health/glp-1-type-1-diabetes-study/index.html   XX Later this month the FDA will conduct a final meeting regarding a new, investigational compound (sotagliflozin) soda-GLIFF-a-zin that has been shown to Improve QoL and Reduce Long-term Complications for people with type 1 diabetes (T1D). The patient advocacy group Taking Control of Your Diabetes (TCOYD.org) is working to inform the T1D community about sotagliflozin - and to encourage people to sign a Change.org petition directed towards FDA.  Last fall, the FDA declined to approve sotagliflozin due to concerns about a potential increased risk of diabetic ketoacidosis (DKA), despite this being a condition that people with T1D on insulin face and manage daily. While TCOYD respects FDA's caution, the group stands by T1D patients and their physicians who, as a team, balance risks and benefits every day. https://tcoyd.org/petition/ XX Dexcom receives FDA approval for it's G7 with 15 day wear. We have an interview with Chief Operating Officer Jake Leach coming up on Tuesday – we talk about the planned roll out of this sensor, what else has changed, and the fine print in the press release – it says    “A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days.   https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Receives-FDA-Clearance-the-Longest-Lasting-Wearable-and-Most-Accurate-CGM-System/default.aspx?utm_source=www.diabetech.info&utm_medium=referral&utm_campaign=dexcom-g7-15-day-sensor-gets-fda-cleared-but-will-it-actually-last-that-long   XX Glucotrack is joining something called  FORGETDIABETES bionic pancreas initiative, - this is an European Union project that aims to develop a long-term automated insulin delivery system for type 1 diabetes patients. Glucotrack's Continuous Blood Glucose Monitor (CBGM) will be integrated into the system to provide real-time glucose readings. The initiative's goal is to create a bionic invisible pancreas that eliminates the need for therapeutic actions and reduces psychological burden.   The architecture of BIP encompasses a ground-breaking, lifelong lasting implanted ip glucose nanosensor; a radically novel ip hormone delivery pump, with unique non-invasive hormone refill with a magnetic docking pill and non-invasive wireless battery recharge; an intelligent closed-loop hormone dosing algorithm, optimized for ip sensing and delivery, individualized, adaptive and equipped with advanced self-diagnostic algorithms.     Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of pain and awkward daily measurement and treatment actions. Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. key feature of BIP is to be fully-implantable and life-long lasting thanks to novel biocompatible and immune-optimized coatings guaranteeing long-term safety and stability https://www.stocktitan.net/news/GCTK/glucotrack-to-participate-in-forgetdiabetes-a-prominent-european-cjjldjb0dq7h.html XX A newly recognised form of diabetes, called Type 5, was announced this week at the World Congress of Diabetes 2025. A global task force will investigate this less-understood condition, which differs from Type 1 and Type 2 diabetes. Type 5 diabetes affects people who are underweight, lack a family history of diabetes and do not show the typical symptoms of Type 1 or Type 2 diabetes. The condition was first observed in the 1960s and referred to as J-type diabetes, after being detected in Jamaica. It was classified by the World Health Organisation in 1985, but removed in 1998 due to lack of physiological evidence. At the time, experts believed it to be a misdiagnosed case of Type 1 or 2 diabetes. New research has since confirmed that Type 5 is different. https://economictimes.indiatimes.com/news/new-updates/a-new-type-of-diabetes-has-been-found-by-scientists-and-it-doesnt-show-the-typical-symptoms-of-type-1-or-type-2/articleshow/120276658.cms?from=mdr   XX Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. A new clinical trial, co-led by endocrinologist and diabetes specialist John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine, has demonstrated that the oral form of semaglutide significantly lowers the risk of cardiovascular events in individuals with type 2 diabetes, atherosclerotic cardiovascular disease, and/or chronic kidney disease. Results from the rather large, international trial were published in the New England Journal of Medicine and presented at the American College of Cardiology's Annual Scientific Session & Expo in Chicago, Illinois.     The effect of oral semaglutide on cardiovascular outcomes was consistent with other clinical trials involving injectable semaglutide, but more trials are needed to determine if one method may be more effective than the other at reducing major cardiovascular events. https://scitechdaily.com/new-pill-form-of-semaglutide-shows-major-benefits-for-people-with-diabetes/ XX April 14 (UPI) -- The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to treat Type 2 diabetes, have been found in the United States. Novo Nordisk, the Danish-headquartered manufacturer, informed the FDA on April 3 that counterfeit 1-milligram injections of semaglutide were being distributed outside its authorized supply chain. The FDA and Novo Nordisk are testing the fake products to identify whether they're safe. Patients are asked to obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product for any signs of counterfeiting. People in possession of the fake product are urged to call Novo Nordisk customer care at 800-727-6500 Monday through Friday from 8:30 a.m. to 6 p.m. EDT and report it to the FDA's criminal activity division's website. Side effects can be reported to FDA's MedWatch Safety Information and Adverse Event Reporting Program (800-FDA-1088 or www.fda.gov/medwatch) as well as to Novo Nordisk, at 800-727-6500. https://www.upi.com/Health_News/2025/04/14/FDA-fake-Ozempic-drugs-Novo-Nordisk/6841744666854/ XX Can a digital lifestyle modification program reduce diabetes risk? A new study shows that the lifestyle intervention significantly reduced 10-year diabetes risk among prediabetics by nearly 46% and increased the diabetes remission rate, highlighting the importance of lifestyle changes. However, the study was not a randomized trial, and participation in the lifestyle intervention was voluntary, which may introduce selection bias. The study evaluated 133,764 adults, categorizing them as diabetic (7.5%), prediabetic (36.2%), and healthy (56.3%), based on fasting glucose and HbA1c levels. https://www.news-medical.net/news/20250414/Digital-lifestyle-program-cuts-diabetes-risk-by-4625-in-prediabetics-study-of-130k2b-adults-reveals.aspx XX Chrissy Teigan is speaking out about her son's type 1 diagnosis – teaming up with Sanofi to encourage people to screen early for Type 1 diabetes.   Teigen got a crash course in the risks of undiagnosed Type 1 diabetes when her 6-year-old son, Miles, was hospitalized with complications of the autoimmune disease last year. The family knew nothing about Type 1 diabetes when Miles was diagnosed during an unexpected medical emergency, Teigen said in a Tuesday announcement. “We were confused and scared when Miles was first diagnosed,” she said in a statement. “There is no doubt in my mind that knowing in advance would have made a positive impact for Miles, me, and our entire family. I want everyone to hear me when I say: stay proactive and talk to your doctor about getting yourself or your loved ones screened for type 1 diabetes today!”   Teigen shared her family's story in a two-minute video on ScreenForType1.com, a Sanofi website that discusses how to get screened for the condition. Miles' diagnosis made Teigen feel like she “went from a mom to a doctor overnight,” she said. That experience is why Teigen said she is “begging you: Do this one thing, and screen yourself and your family for Type 1 diabetes.” https://www.fiercepharma.com/marketing/sanofi-signs-chrissy-teigen-diabetes-screening-campaign XX Dr. Richard Bernstein – best known for his advocacy around low carb diets for people with diabetes – died this week at the age of 90. Born in 1934 in Brooklyn, New York, he was diagnosed with type 1 at age 12. In the 1970s he adapted a blood glucose monitor for home use and helped pioneer home glucose monitoring. He published multiple books on Diabetes including the #1 selling Diabetes book on Amazon.Com “Dr. Bernstein's Diabetes Solution: A Complete Guide to Achieving Normal Blood Sugars” and “Diabetes Type II: Living a Long, Healthy Life Through Blood Sugar Normalization”.  He practiced and saw patients right up until his death.

Errol Morris movie about investing.  Dan liked it.  Also A Real Pain.  Saving the Metro Theater (NYC).  Kelvin Sampson.  Remembering William Finn.  Richard Bernstein.  Linda Williams, professor, and how her porno-film theories intersected with Dan's legal career.  Clive Revill. Credits: Talent:  Tamsen Granger and Dan Abuhoff Engineer:  Ellie Suttmeier Art:  Zeke Abuhoff

Join hosts Matt Zeigler and Justin Carbonneau as they sit down with Richard Bernstein, CEO and Chief Investment Officer of Richard Bernstein Advisors. In this insightful conversation, Rich shares his expert perspective on today's market challenges, including the unprecedented narrowness of recent markets, the impact of tariffs on the US economy, and why the current environment calls for a shift toward value investing and greater diversification. Drawing on decades of experience, Bernstein offers practical wisdom for navigating today's uncertain investment landscape.Topics Covered:The difference between the 2008 financial crisis and today's economic challengesWhy 2023-2024 saw the most narrow stock market since the Great DepressionThe potential impact of tariffs as "the biggest tax on consumers in our professional careers"Why investors should err on the side of value over growth in the current marketHow US debt levels impact interest rates and economic competitivenessThe role of the Federal Reserve as a lagging rather than leading indicatorWhy gold serves as an effective hedge against uncertaintyBernstein's skeptical view on cryptocurrency and Bitcoin valuationThe limitations of index funds in today's market environmentTimeless advice for wealth building: stick to fundamentals and avoid "get rich quick" thinking

Richard Bernstein Advisors CEO Richard Bernstein says "the Fed is caught between a rock and a hard place. GDP forecast has been downward, but inflation expectations seem poised to accelerate." Bernstein spoke with Bloomberg's Jonathan Ferro, Lisa Abramowicz and Annmarie Hordern.See omnystudio.com/listener for privacy information.

What happens when you combine an uncertain macro environment with an incredibly certain investor base? You get a whole lot of volatility, according to Richard Bernstein. Bernstein is the CEO and Chief Investment Officer at Richard Bernstein Advisors. He joins Ricky Mulvey for a conversation about: - Trade wars - Degloblalization - The crypto industry - And how investors ought to make sense of the news. Host: Ricky Mulvey Guest: Richard Bernstein Producer: Mary Long Engineer: Rick Engdahl Learn more about your ad choices. Visit megaphone.fm/adchoices

Dan Suzuki serves as the Deputy Chief Investment Officer of Richard Bernstein Advisors (RBA). Dan shares his take on a wide range of topics that have recently influenced investor sentiment and moved markets, including US trade policy, growth concerns, and the progression of artificial intelligence. We also outline a market outlook and discuss asset allocation considerations. Host: Daniel Cassidy Recorded on 03.13.25.

Companies, investors, and countries are all having a hard time knowing what the future holds. And that makes forecasting hard. (00:21) Jason Moser and Matt Argersinger discuss: - The market's correction reaction to tariffs, and what higher prices might mean for consumers that are already spending less. - The market's questions around Tesla's tough start to 2025, slipping european sales, and Elon Musk. - Earnings from Adobe, Vail, and Docusign. (19:22) Macro-focused investor Richard Bernstein walks Ricky Mulvey through the big picture he's seeing, and how tariffs, trade uncertainty, and how it all flows into what we've seen in the stock market over the past few weeks. (32:51) Jason and Matt break down where they turn to celebrate Pi Day and two stocks on their radar: Ansys and Starbucks. Stocks discussed: TSLA, ADBE, MTN, DOCU, ANSS, SBUX Host: Dylan Lewis Guests: Jason Moser, Matt Argersinger, Richard Bernstein, Ricky Mulvey Engineers: Dan Boyd Learn more about your ad choices. Visit megaphone.fm/adchoices

Harry and Daniel are joined by special guest Richard Bernstein, author of Only in America, to explore the groundbreaking yet controversial 1927 film The Jazz Singer. As the first feature-length "talkie," The Jazz Singer revolutionized Hollywood, but its themes of assimilation, the American Dream, and generational conflict remain just as compelling today.The conversation delves into Al Jolson's electrifying performance, the film's cultural impact, and the complicated legacy of both the movie and its star—including the troubling use of blackface, which continues to spark debate.Plus, they trace The Jazz Singer's origins—from short story to stage play to cinematic milestone—and consider how it shaped portrayals of Jewish identity on screen. Tune in for a fascinating discussion about one of the most significant (and controversial) films in Jewish and Hollywood history.Buy Richard's book, Only in America - https://bookshop.org/p/books/only-in-america-al-jolson-and-the-jazz-singer-richard-bernstein/20143816The Jazz Singer on IMDb - https://www.imdb.com/title/tt0018037/The Jazz Singer on YouTube - https://youtu.be/PMvn8Ws-l0cConnect with Jews on Film online:Jews on Film Merch - https://jews-on-film.printify.me/productsInstagram - https://www.instagram.com/jewsonfilm/Twitter - https://twitter.com/jewsonfilmpodYouTube - https://www.youtube.com/@jewsonfilmTikTok - https://www.tiktok.com/@jewsonfilmpod

Richard Bernstein is a reporter, foreign correspondent, and cultural critic whose latest book is Only in America: Al Jolson and The Jazz Singer. Co-hosts: Jonathan Friedmann & Joey Angel-Field Producer-engineer: Mike Tomren Richard's websitehttps://www.richardbernstein.net/ Only in Americahttps://www.penguinrandomhouse.com/books/703276/only-in-america-by-richard-bernstein/ The Jazz Singer (1927)https://www.youtube.com/watch?v=PMvn8Ws-l0c Amusing Jews Merch Storehttps://www.amusingjews.com/merch#!/ Subscribe to the Amusing Jews podcasthttps://www.spreaker.com/show/amusing-jews Adat Chaverim – Congregation for Humanistic Judaism, Los Angeleshttps://www.humanisticjudaismla.org/ Jewish Museum of the American Westhttps://www.jmaw.org/ Atheists United Studioshttps://www.atheistsunited.org/au-studios

Today's guest is Chuck Clough, Chief Investment Officer of Clough Capital. Chuck is well known from his time as the Chief Global Investment Strategist at Merrill Lynch until 2000 and has spent over six decades in finance. In today's episode, Chuck shares insights from his illustrious career, reflecting on the challenges of the 1970s and the market crash of 1987. Chuck explains what it was like to be bearish during the dot-com bubble and watch Cisco go up 6x after he turned bearish, only to then decline by 95%. He compares the current stock market to the dot-com bubble, talks about the impact of AI on various sectors, and finishes with lessons from working alongside legends like Bob Farrell & Richard Bernstein. (0:00) Starts (0:34) Sponsor: Farmland LP (1:40) Introduction of Chuck Clough (5:14) 1970s inflation (11:57) Comparing the 1999 dot-com bubble to today (14:08) Predictions for AI companies (24:13) Clough Capital and views on China (28:09) Interest rates, inflation, and demographics (33:09) Savings, investment, and the productivity impact of AI (38:30) Investment opportunities in various industries (47:11) Contrarian views (50:50) Financial market surprises (56:37) Chuck's most memorable investment ----- For detailed show notes, click here ----- Farmland LP is one of the largest investment funds in the US focused on converting chemical-based conventional farmland to organic, sustainably-managed farmland using a value-add commercial real estate strategy in the agriculture sector. Register here for their webinar on March 12.  ----- Follow Meb on X, LinkedIn and YouTube To learn more about our funds and follow us, subscribe to our mailing list or visit us at cambriainvestments.com Follow The Idea Farm: X | LinkedIn | Instagram | TikTok ----- Interested in sponsoring the show? Email us at Feedback@TheMebFaberShow.com ----- Past guests include Ed Thorp, Richard Thaler, Jeremy Grantham, Joel Greenblatt, Campbell Harvey, Ivy Zelman, Kathryn Kaminski, Jason Calacanis, Whitney Baker, Aswath Damodaran, Howard Marks, Tom Barton, and many more.  ----- Meb's invested in some awesome startups that have passed along discounts to our listeners. Check them out here!  ----- Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). The Clough ETFs are distributed by Paralel Distributors, LLC. Paralel Distributors, LLC and Clough Capital Partners L.P. are not affiliated. Please read Clough Capital's disclosures and a prospectus at cloughetfs.com/disclosures before investing. Learn more about your ad choices. Visit megaphone.fm/adchoices

Why Must I Die (1960)AIP Production #504 Jeff and Cheryl strap in for an emotional tale about the application (and misapplication) of the death penalty in Why Must I Die. Directed by Roy Del Ruth Screenplay by Richard Bernstein and George W. Waters Story by George W. Waters Produced by Richard Bernstein Cast:Terry Moore as Lois King Debra Paget as Dottie Manson Bert Freed as Adler Juli Reding as Mitzi Lionel Ames as Eddie Rainey Richard Le Pore as Sinclair Sid Melton as Morrie Waltzer Selette Cole as Peggy Taylor Dorothy Lovett as Mrs Benson Phil Harvey as Kenny Randall Fred Sherman as Red King Robert Shayne as Charlie Munro Damian O'Flynn as District Attorney Walter Dennison Holly Harris as Miss Bradley, the Superintendent Mark Sheeler as Jim Jhean Burton as Trixie Abbagail Shelton as Dawn Jackie Joseph as Marge Brennan the Cigarette Girl (uncredited)  A Viscount-Terry Moore Production An American International Picture 

Send us a textBethany McKenzie was thrust into the world of type one diabetes when her son was diagnosed with the disease in 2015. She discovered this when Bethany came back from a trip, when she noticed her son, River,  had lost weight, dropping from 46 to 40 lbs. Immediately, she rushed him to the hospital, and he was diagnosed. For several years, Bethany followed their rules, only to find that her son felt truly terrible and unhealthy, experiencing headaches, and high blood sugar.Eventually, she realized that she would have to change the way that her family ate, despite the advice from her doctors and dieticians. Bethany found low-carbohydrate diets that have, with careful control, worked wonders for her son and for her family.She is the executive producer of the incredible documentary “The Diabetes Solution”, modeled after the work of Dr. Richard Bernstein in the field of diabetes and insulin.She is also the founder of Let Me Be 83, a movement by the Rivere Foundation. They advocate for an alternative diabetes management regimen, anchored in nutrition and the proper use of insulins, that allows people with diabetes to achieve healthy blood glucose levels. Find Bethany at-FB- @Let Me Be 83https://letmebe83.org/about/Find Boundless Body at- myboundlessbody.com Book a session with us here!

Join us for an inspiring and thought-provoking conversation with Supreme Court Justice Richard Bernstein, a longtime friend of MJE and a true testament to perseverance and vision. Born blind, Justice Bernstein has defied expectations, becoming a trailblazer in law, an advocate for peace, and a marathon runner who challenges limits in every aspect of life.In this episode, we delve into his remarkable journey, including his role in advancing the Abraham Accords and promoting peace in the Middle East. Justice Bernstein shares profound insights on the beauty of his disability, his unwavering faith in God, and how it has shaped his perspective on justice, resilience, and advocacy.0:00 Introduction2:43 Serving as a Judge in MI4:00 Resilience10:15 Resilience15:15 Identifying Purpose Through Judaism16:02 Wrongful Convictions20:34 Flint Water Case23:26 Talmudic Perspective on Wrongful Convictions24:18 Has DNA Been Helpful in Court?28:47 Overcoming Adversity with One's Mission35:26 Disability Advocacy in the Middle East50:04 Importance if the Abraham Accords52:18 Rabbi Nebenzahl59:07 Everybody is Touched by Disability1:00:32 Perception of Disabilities in the Arab World1:04:25 Collaboration with a Sheikh1:07:21 Peace with Saudi Arabia1:08:41 Opening MI Back Up During Covid1:11:15 Long Term Consequences of Covid Lockdown1:13:56 Bringing People Together1:16:23 Conclusion

Richard Bernstein provides his perspective on key investment themes to watch in the year ahead, including overlooked opportunities, potential pitfalls, and the value of seeking “maximum diversification”.----------------------------------------------------------------------------------------------Website: First Trust PortfoliosConnect with us on LinkedIn: First Trust LinkedInFollow us on X: First Trust on XSubscribe to the First Trust YouTube ChannelSubscribe to the ROI Podcast YouTube Channel

Send us a textR.D. Dikeman, PhD, is a theoretical physicist and loving husband of Roxanne Dikeman, PhD, a clinical psychologist. Their world was turned upside down when their young son David was diagnosed with type 1 diabetes.After following conventional dietary advice for this condition led to uncontrollable blood sugar, dangerous “hypos,” and many sleepless nights, R.D. discovered the work of Dr. Richard Bernstein, MD, a medical doctor who has used a low-carb diet to control his own type 1 diabetes for more than fifty years and pioneered some of the most groundbreaking research on low-carb diets for diabetes in the modern era.Through working closely with Dr. Bernstein and as a founder of the TypeOneGrit online community, R.D. has helped provide thousands of other individuals and families living with type 1 diabetes with information to reduce the threat of complications and attain the truly normal blood sugars that all type 1 diabetics deserve.TypeOneGrit is an amazing FB group of type 1 diabetics who are following Dr. Bernstein and his protocol which consists of a VERY low carb diet- no grains, no sugar, no starch, and no fruit, to normalize blood sugars.Find RD Dikeman at-FB- @typeonegritFB- @DiabetesUniversityTW- @DikemanDaveResources-Amazon- Dr. Bernstein's Diabetes Solution: The Complete Guide to Achieving Normal Blood Sugarshttps://letmebe83.org/Find Boundless Body at- myboundlessbody.com Book a session with us here!

As 2025 quickly approaches, Rich rejoins Jason for a year-ahead discussion, spanning the macroeconomic environment, to markets, to the landscape across Washington DC. We also spend time reviewing investment themes in-focus, along with allocation preferences across asset classes. Featured are Jason Draho, Head of Asset Allocation Americas with the UBS Chief Investment Office, and Richard Bernstein, Founder, Chief Executive Officer and Chief Investment Officer of Richard Bernstein Advisors (RBA). Host: Daniel Cassidy

Mike Contopoulos rejoins Leslie Falconio for a discussion around year-end asset class performance expectations, potential outcome implications of the US election for fixed income investors, positioning, and more. Featuring Mike Contopoulos, Director of Fixed Income for Richard Bernstein Advisors, as well as Leslie Falconio, Head of Taxable Fixed Income Strategy Americas with the UBS Chief Investment Office. Host: Daniel Cassidy

Dan Suzuki serves as the Deputy Chief Investment Officer for Richard Bernstein Advisors (RBA). Dan drops by the 1285 podcast studio in New York to share his US economic outlook, thoughts on Q3 corporate earnings, equity valuations, monetary policy, and more. Plus, we spend time highlighting where opportunities can be located. Host: Daniel Cassidy

Part 2 of 2 Noted strategist and asset allocator Rich Bernstein shares the most important investment lessons learned from the markets in the 20 years since WEALTHTRACK launch, in part 2 of his interview. WEALTHTRACK episode 2102 broadcast on July 12, 2024 More info: https://wealthtrack.com/key-investment-lessons-of-the-last-20-years-from-noted-strategist-richard-bernstein/ Bookshelf: Bookshelf: Navigate the Noise: Investing in the New Age of Media and Hype https://amzn.to/3VRLCvA Stocks for the Long Run, 6th Edition https://amzn.to/3Wh25uJ --- Support this podcast: https://podcasters.spotify.com/pod/show/wealthtrack/support

Influential strategist Richard Bernstein reflects on the most successful investment themes of the last twenty years and explains why deglobalization and the concomitant reindustrialization of America are his number one themes now. More info: https://wealthtrack.com/strategist-richard-bernstein-on-successful-investment-themes-of-the-past-and-his-favorite-one-now/ Bookshelf: Navigate the Noise: Investing in the New Age of Media and Hype https://amzn.to/3VRLCvA --- Support this podcast: https://podcasters.spotify.com/pod/show/wealthtrack/support

On episode 130 of The Compound and Friends, Michael Batnick and Downtown Josh Brown are joined by Richard Bernstein to discuss: the magnificent 7 compared to past bubbles, bitcoin as a sentiment indicator, the Fed's predicament, the case for international stocks, and much more! Thanks to Carta for sponsoring this episode. See how Carta can simplify your equity plan management today by going to carta.com/compound. Check out the latest in financial blogger fashion at The Compound shop: https://www.idontshop.com Investing involves the risk of loss. This podcast is for informational purposes only and should not be or regarded as personalized investment advice or relied upon for investment decisions. Michael Batnick and Josh Brown are employees of Ritholtz Wealth Management and may maintain positions in the securities discussed in this video. All opinions expressed by them are solely their own opinion and do not reflect the opinion of Ritholtz Wealth Management. The Compound Media, Incorporated, an affiliate of Ritholtz Wealth Management, receives payment from various entities for advertisements in affiliated podcasts, blogs and emails. Inclusion of such advertisements does not constitute or imply endorsement, sponsorship or recommendation thereof, or any affiliation therewith, by the Content Creator or by Ritholtz Wealth Management or any of its employees. For additional advertisement disclaimers see here https://ritholtzwealth.com/advertising-disclaimers. Investments in securities involve the risk of loss. Any mention of a particular security and related performance data is not a recommendation to buy or sell that security. The information provided on this website (including any information that may be accessed through this website) is not directed at any investor or category of investors and is provided solely as general information. Obviously nothing on this channel should be considered as personalized financial advice or a solicitation to buy or sell any securities. See our disclosures here: https://ritholtzwealth.com/podcast-youtube-disclosures/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode 2429 - On this Friday's show Vinnie Tortorich welcomes back Dr. Ryan Attar and they discuss making noise about diabetes, GLP-1s, and more. https://vinnietortorich.com/2023/12/making-noise-dr-ryan-attar-episode-2429 PLEASE SUPPORT OUR SPONSORS   YOU CAN WATCH THIS EPISODE ON YOUTUBE - Making Noise Dr. Ryan Attar became a Type 1 diabetic in his adult years. (2:30) Type 1 diabetes used to be called "childhood diabetes." You can become T1D at any age. Vinnie shares his friend Bethany McKenzie's story. (6:25) Her child is T1D, but she and her husband were able to find ways to help their child. When she shared what she was doing with her doctor, his response was disturbing. Ryan explains more about T1D and the program he uses based on the research of Dr. Richard Bernstein. (10:30) Vinnie wants to know why there is so much pushback from the ADA and the diabetic and medical communities. (16:45) Ryan is making noise on X by challenging Dr. Bob Gabbay and the ADA. He discusses the “standard of care” document the ADA releases each year and his problems with it. The popularity of GLP-1 medications is (and isn't) astounding. Yes, a person can lose weight on those medications, but they damage your gut, muscles, and bones. The ADA accepts donations from Big Parma. It seems most people just expect to be on a slew of medications by the time they reach age 50. They discuss the problems they have with prominent vegan doctors. (40:00) You can find Dr. Rayan Attar at [the_ad id="20253"] PURCHASE BEYOND IMPOSSIBLE (2022) The documentary launched on January 11! Order it TODAY! This is Vinnie's third documentary in just over three years. Get it now on Apple TV (iTunes) and/or Amazon Video! Link to the film on Apple TV (iTunes):  Then, Share this link with friends, too! It's also now available on Amazon (the USA only for now)!  Visit my new Documentaries HQ to find my films everywhere: REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere: Then, please share my fact-based, health-focused documentary series with your friends and family. The more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: Then, please share my fact-based, health-focused documentary series with your friends and family. The more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter!